Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness
Status:
Unknown status
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Cilostazol is an antiplatelet agent used to reduce the symptoms of intermittent claudication.
Cilostazol inhibits phosphodiesterase III (PDE III), which causes it to be a vasodilator and
inhibitor of platelet aggregation. Recently there were report of beneficial effect of
cilostazol like vasodilation, lipid metabolism, and cytokine production. But there were few
clinical studies that support these effects of cilostazol. The purpose of this study is to
evaluate the vasodilatory and anti-inflammatory effect of cilostazol presented by PWV and
plasma adipocytokines.